medigraphic.com
ISSN 1561-3127 (Electronic)
ISSN 0864-3466 (Print)

2022, Number 3

<< Back Next >>

Revista Cubana de Salud Pública 2022; 48 (3)

Experience of chloroquine use in COVID-19 patients

Suárez DT, González TR, Acosta GFA, Oliva VE, Rodríguez RSF, Cabeza EI, Acosta PY

Language: Spanish
References: 29
Page: 1-17
PDF size: 509.15 Kb.


ABSTRACT

Introduction: COVID-19 is a pandemic without specific treatment at the time of this study. Chloroquine has been one of the drugs applied due to its in vitro antiviral effects.
Objective: To identify the effect of chloroquine on patients treated with COVID-19 in relation to humoral parameters, hospital stay, complications and mortality.
Methods: Retrospective observational study, with 181 positive cases of SARS-CoV-2, divided into two study groups according to use. Group 1 (n = 154) those treated with chloroquine and group 2 (n = 27) those who did not receive it. Personal pathological history, antimicrobial treatment, humoral parameters were identified at admission and between the sixth and eighth day of admission, hospital stay, complications and death. The squared ji test, Mann-Whitney U test and Wilcoxon's sign rank test were used according to convenience.
Results: Group 2 had a higher proportion of arrhythmia (n = 4; 14.8%), dementia (n = 2; 7.4%), other background (n = 12; 44.4%) and higher values of leukocytes (m = 7.25 x 109/L; RIC: 4.55 – 9.55 vs. m = 4.8 x 109/L; RIC: 3.95 – 6.8) and alkaline phosphatase (m = 94 U/L; RIC: 84 – 125 vs. m = 83 U/L; RIC: 66 – 98) that group 1 upon admission. All humoral parameters on the sixth and eighth days, hospital stay, and proportions of complications and death in both groups were similar.
Conclusions: No effect attributable to the use of chloroquine on patients with COVID-19 was identified in terms of humoral parameters, hospital stay, frequency of complications or mortality.


REFERENCES

  1. Organización Mundial de la Salud. Cronología de la respuesta de la OMS a la COVID-19.Ginebra: OMS; 2020 [acceso 01/08/2021]. Disponible en:https://www.who.int/es/news/item/29-06-2020-covidtimeline

  2. Redacción MINSAP. Nota informativa sobre el nuevo coronavirus en Cuba [Sitio WebOficial del Ministerio de Salud Pública]. La Habana: Minsap [actualizado 24/08/2021; acceso24/08/2021]. Disponible: https://salud.msp.gob.cu/nota-informativa-sobre-el-nuevocoronavirus-en-cuba/

  3. OPS/OMS. Cuba frente a la covid-19. Boletín de la OPS/OMS en Cuba. 2020 [acceso24/08/2021];24(2):48. Disponible en:https://iris.paho.org/bitstream/handle/10665.2/52514/v24n2.pdf.pdf?sequence=1&isAllowed=y

  4. Ministerio de Salud Pública. Protocolo de actuación nacional para la COVID-19 Versión1.6. La Habana: Minsap; 2021 [acceso 24/08/2021]. 227 p. Disponible en:https://files.sld.cu/editorhome/files/2021/03/Protocolo-COVID19-Cuba_versi%c3%b3n-1.6.pdf

  5. Ministerio de Salud Pública. Protocolo de actuación nacional para la COVID-19 Versión1.4. La Habana: Minsap; 2020 [acceso 24/08/2021]. 132p. Disponible:https://covid19cubadata.github.io/protocolos/protocolo-version-4.pdf

  6. Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on theefficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care. 2020 [acceso28/08/2021];57:279-83. Disponible en:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7270792/

  7. Li K, Chen D, Chen S, Feng Y, Chang C, Wang Z, et al. Predictors of fatality includingradiographic findings in adults with COVID-19. Respiratory Research. 2020 [acceso28/08/2021];21(1). Disponible en: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85086425051&doi=10.1186%2fs12931-020-01411-2&partnerID=40&md5=809aa4408967ef13fb9a8f9e0ea928fc

  8. Paton NI, Lee L, Xu Y, Ooi EE, Cheung YB, Archuleta S, et al. Chloroquine for influenzaprevention: a randomized, double-blind, placebo-controlled trial. The Lancet Infectious Diseases. 2011 [acceso 28/08/2021];11(9):677-83. Disponible en:https://www.sciencedirect.com/science/article/pii/S1473309911700652

  9. Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, et al.Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virologyjournal. 2005 [acceso 28/08/2021];2:69. Disponible en:https://virologyj.biomedcentral.com/track/pdf/10.1186/1743-422X-2-69

  10. Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, et al. Hydroxychloroquine, a less toxicderivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. CellDiscovery. 2020 [acceso 24/08/2021];6(1). Disponible en:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7078228/

  11. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al.Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-labelnon-randomized clinical trial. Int J Antimicrob Agents. 2020 [acceso28/08/2021];56(1):105949. Disponible en:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102549/pdf/main.pdf

  12. Rodrigo C, Fernando SD, Rajapakse S. Clinical evidence for repurposing chloroquineand hydroxychloroquine as antiviral agents: a systematic review. Clinical Microbiology andInfection. 2020 [acceso 28/08/2021];26(8):979-87. Disponible:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7250111/

  13. Lyngbakken MN, Berdal JE, Eskesen A, Kvale D, Olsen IC, Rueegg CS, et al. Apragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine oncoronavirus disease 2019 viral kinetics. Nat Commun. 2020 [acceso 28/08/2021];11(1):5284.Disponible en: https://www.nature.com/articles/s41467-020-19056-6.pdf

  14. Hashem AM, Alghamdi BS, Algaissi AA, Alshehri FS, Bukhari A, Alfaleh MA, et al.Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viralinfections: A narrative review. Travel medicine and infectious disease. 2020 [acceso28/08/2021];35:101735. Disponible en:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7202851/

  15. Moiseev S, Avdeev S, Brovko M, Novikov P, Fomin V. Is there a future forhydroxychloroquine/chloroquine in prevention of SARS-CoV-2 infection (COVID-19) AnnRheum Dis. 2021 [acceso 28/08/2021];80(2):e19. Disponible en: https://ard.bmj.com/content/annrheumdis/early/2020/05/20/annrheumdis-2020-217570.full.pdf

  16. González Tabares R, Acosta González FA, Oliva Villa E, Rodríguez Reyes SF, CabezaEchevarría I. Predictores de mal pronóstico en pacientes con la COVID-19. Revista Cubanade Medicina Militar. 2020 [acceso 28/08/2021];49(4):e0200918. Disponible en:http://www.revmedmilitar.sld.cu/index.php/mil/article/view/918

  17. Zhang S-Y, Lian J-S, Hu J-H, Zhang X-L, Lu Y-F, Cai H, et al. Clinical characteristicsof different subtypes and risk factors for the severity of illness in patients with COVID-19in Zhejiang, China. Infectious Diseases of Poverty. 2020;9(1):85. DOI: 10.1186/s40249-020-00710-6

  18. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors formortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.Lancet. 2020 [acceso 28/08/2021];395(10229):1054-62. Disponible en:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7270627/pdf/main.pdf

  19. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk Factors Associated with AcuteRespiratory Distress Syndrome and Death in Patients with Coronavirus Disease 2019Pneumonia in Wuhan, China. JAMA Internal Medicine. 2020 [acceso28/08/2021];180(7):934-43. Disponible en:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7070509/

  20. Abella BS, Jolkovsky EL, Biney BT, Uspal JE, Hyman MC, Frank I, et al. Efficacy andSafety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 ProphylaxisAmong Health Care Workers: A Randomized Clinical Trial. JAMA Intern Med. 2021[acceso 28/08/2021];181(2):195-202. Disponible en:https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2771265

  21. Abd-Elsalam S, Esmail ES, Khalaf M, Abdo EF, Medhat MA, Abd El Ghafar MS, et al.Hydroxychloroquine in the Treatment of COVID-19: A Multicenter Randomized ControlledStudy. The American journal of tropical medicine and hygiene. 2020 [acceso28/08/2021];103(4):1635-9. Disponible en:https://www.ajtmh.org/downloadpdf/journals/tpmd/103/4/article-p1635.xml

  22. Cavalcanti AB, Zampieri FG, Rosa RG, Azevedo LCP, Veiga VC, Avezum A, et al.Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. The New England journal of medicine. 2020 [acceso 28/08/2021];383(21):2041-52. Disponible en:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7397242/pdf/NEJMoa2019014.pdf

  23. Chen CP, Lin YC, Chen TC, Tseng TY, Wong HL, Kuo CY, et al. A multicenter,randomized, open-label, controlled trial to evaluate the efficacy and tolerability ofhydroxychloroquine and a retrospective study in adult patients with mild to moderatecoronavirus disease 2019 (COVID-19). PLoS One. 2020 [acceso28/08/2021];15(12):e0242763. Disponible en:https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7710068/

  24. Horby P, Mafham M, Linsell L, Bell JL, Staplin N, Emberson JR, et al. Effect ofHydroxychloroquine in Hospitalized Patients with Covid-19. The New England journal ofmedicine. 2020 [acceso 28/08/2021];383(21):2030-40. Disponible en:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556338/pdf/NEJMoa2022926.pdf

  25. Self WH, Semler MW, Leither LM, Casey JD, Angus DC, Brower RG, et al. Effect ofHydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19:A Randomized Clinical Trial. Jama. 2020 [acceso 28/08/2021];324(21):2165-76. Disponibleen:https://jamanetwork.com/journals/jama/fullarticle/2772922?appid=scweb&appid=scweb

  26. Huang M, Tang T, Pang P, Li M, Ma R, Lu J, et al. Treating COVID-19 withChloroquine. Journal of molecular cell biology. 2020 [acceso 28/08/2021];12(4):322-5.Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7232130/pdf/mjaa014.pdf

  27. Huang M, Li M, Xiao F, Pang P, Liang J, Tang T, et al. Preliminary evidence from amulticenter prospective observational study of the safety and efficacy of chloroquine for thetreatment of COVID-19. National Science Review. 2020;7(9):1428-36. DOI:10.1093/nsr/nwaa113

  28. Borba MGS, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, Brito M, et al. Effectof High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for PatientsHospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)Infection: A Randomized Clinical Trial. JAMA Network Open. 2020;3(4):e208857. DOI:10.1001/jamanetworkopen.2020.8857

  29. Pan H, Peto R, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V, Abdool Karim Q,et al. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. The New England journal of medicine. 2021 [acceso 28/08/2021];384(6):497-511. Disponible en:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7727327/pdf/NEJMoa2023184.pdf




2020     |     www.medigraphic.com